AMARIN CORP PLC -ADR(NASDAQ:AMRN) stock News

AMRN Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Zacks Investment Research - Mentions: PRTA

Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?

a month ago - By: Amarin Corporation plc

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

a month ago - By: Amarin Corporation plc

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

a month ago - By: Amarin Corporation plc

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

2 months ago - By: Benzinga - Mentions: ALL ZIMV NEU LRCX ...

Earnings Scheduled For July 30, 2025

a month ago - By: Amarin Corporation plc

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

2 months ago - By: Amarin Corporation plc

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

2 months ago - By: Amarin Corporation plc

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

2 months ago - By: Zacks Investment Research - Mentions: ANIP

Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

2 months ago - By: Zacks Investment Research - Mentions: RCKT AKRO ALGS

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

2 months ago - By: Zacks Investment Research - Mentions: ALLO AKRO ALGS

Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus

2 months ago - By: Zacks Investment Research

Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

2 months ago - By: Amarin Corporation plc

Amarin Reports Second Quarter 2025 Financial Results

2 months ago - By: Amarin Corporation plc

Amarin Reports Second Quarter 2025 Financial Results

3 months ago - By: Amarin Corporation plc

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

3 months ago - By: Amarin Corporation plc

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

4 months ago - By: Benzinga

Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA

4 months ago - By: Amarin Corporation plc

Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe

4 months ago - By: Amarin Corporation plc

Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe

4 months ago - By: Zacks Investment Research - Mentions: REGN SNY EXEL

Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid

4 months ago - By: Zacks Investment Research - Mentions: LXRX KURA CMMB

KURA Stock Rises More Than 15% This Past Week: Here's Why

4 months ago - By: Zacks Investment Research - Mentions: LXRX ZTS

Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?

4 months ago - By: Zacks Investment Research - Mentions: LXRX LYRA

Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success

4 months ago - By: Zacks Investment Research - Mentions: JNJ LXRX

JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer

4 months ago - By: Zacks Investment Research - Mentions: SNY BPMC

Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines

5 months ago - By: Zacks Investment Research - Mentions: LXRX IMVT

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus

5 months ago - By: Zacks Investment Research - Mentions: JNJ ORIC

ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study

5 months ago - By: Zacks Investment Research - Mentions: BMY LXRX

BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications

5 months ago - By: Zacks Investment Research - Mentions: LXRX CMMB CADL

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

5 months ago - By: Zacks Investment Research - Mentions: GSK

Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year?

5 months ago - By: Yahoo Finance - Mentions: NVDA TTEK ATMU COMP ...

Wall Street ends up with Nvidia, appeals court reinstates Trump tariffs

5 months ago - By: Zacks Investment Research - Mentions: LXRX RCKT CMMB

RCKT Stock Tanks on Patient Death in Danon Disease Study

5 months ago - By: Zacks Investment Research - Mentions: TEVA LXRX CMMB

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

5 months ago - By: Zacks Investment Research - Mentions: LXRX VSTM

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

5 months ago - By: Zacks Investment Research - Mentions: AZN HALO LXRX

AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer

5 months ago - By: Zacks Investment Research - Mentions: GSK HALO LXRX

AMARIN CORP PLC -ADR (AMRN) Stock News

AMRN Latest News, Press Relases and Analysis

Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Earnings Scheduled For July 30, 2025

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus

Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Amarin Reports Second Quarter 2025 Financial Results

Amarin Reports Second Quarter 2025 Financial Results

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA

Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe

Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe

Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid

KURA Stock Rises More Than 15% This Past Week: Here's Why

Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?

Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success

JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer

Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus

ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study

BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year?

Wall Street ends up with Nvidia, appeals court reinstates Trump tariffs

RCKT Stock Tanks on Patient Death in Danon Disease Study

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer

GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma